S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.36 (+0.40%)
META   488.78 (+0.98%)
GOOGL   137.33 (+0.70%)
AMZN   174.94 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.86 (+2.09%)
NIO   5.66 (+4.24%)
AMD   190.47 (+7.89%)
BABA   74.08 (-0.68%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.94 (+0.26%)
CGC   3.27 (-2.68%)
GE   156.11 (+0.32%)
DIS   111.08 (+0.25%)
AMC   4.27 (-14.43%)
PFE   26.77 (-1.00%)
PYPL   60.18 (-0.12%)
XOM   104.53 (+0.20%)
S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.36 (+0.40%)
META   488.78 (+0.98%)
GOOGL   137.33 (+0.70%)
AMZN   174.94 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.86 (+2.09%)
NIO   5.66 (+4.24%)
AMD   190.47 (+7.89%)
BABA   74.08 (-0.68%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.94 (+0.26%)
CGC   3.27 (-2.68%)
GE   156.11 (+0.32%)
DIS   111.08 (+0.25%)
AMC   4.27 (-14.43%)
PFE   26.77 (-1.00%)
PYPL   60.18 (-0.12%)
XOM   104.53 (+0.20%)
S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.36 (+0.40%)
META   488.78 (+0.98%)
GOOGL   137.33 (+0.70%)
AMZN   174.94 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.86 (+2.09%)
NIO   5.66 (+4.24%)
AMD   190.47 (+7.89%)
BABA   74.08 (-0.68%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.94 (+0.26%)
CGC   3.27 (-2.68%)
GE   156.11 (+0.32%)
DIS   111.08 (+0.25%)
AMC   4.27 (-14.43%)
PFE   26.77 (-1.00%)
PYPL   60.18 (-0.12%)
XOM   104.53 (+0.20%)
S&P 500   5,081.63 (+0.23%)
DOW   38,898.63 (-0.13%)
QQQ   437.93 (+0.61%)
AAPL   180.03 (-0.77%)
MSFT   409.36 (+0.40%)
META   488.78 (+0.98%)
GOOGL   137.33 (+0.70%)
AMZN   174.94 (+1.03%)
TSLA   199.87 (-1.07%)
NVDA   792.86 (+2.09%)
NIO   5.66 (+4.24%)
AMD   190.47 (+7.89%)
BABA   74.08 (-0.68%)
T   17.00 (+0.24%)
F   12.41 (+0.89%)
MU   89.94 (+0.26%)
CGC   3.27 (-2.68%)
GE   156.11 (+0.32%)
DIS   111.08 (+0.25%)
AMC   4.27 (-14.43%)
PFE   26.77 (-1.00%)
PYPL   60.18 (-0.12%)
XOM   104.53 (+0.20%)

Stoke Therapeutics (STOK) Stock Forecast & Price Target

$7.90
-0.06 (-0.75%)
(As of 02:27 PM ET)

Stoke Therapeutics Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Moderate Buy
Based on 8 Analyst Ratings

Analysts' Consensus Price Target

$21.00
165.82% Upside
High Forecast$35.00
Average Forecast$21.00
Low Forecast$12.00
TypeCurrent Forecast
3/1/23 to 2/29/24
1 Month Ago
1/30/23 to 1/30/24
3 Months Ago
12/1/22 to 12/1/23
1 Year Ago
3/1/22 to 3/1/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$21.00$21.00$21.00$25.17
Predicted Upside165.82% Upside198.72% Upside198.72% Upside164.68% Upside
Get Stoke Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.


STOK Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

STOK Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Stoke Therapeutics Stock vs. The Competition

TypeStoke TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.68
2.48
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside167.18% Upside1,855.32% Upside7.47% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/16/2024Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$14.00+163.65%
8/8/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$18.00 ➝ $14.00+149.55%
8/8/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$23.00+293.16%
8/8/2023HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$35.00+498.29%
7/25/2023TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/1/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Neutral$9.00 ➝ $12.00+34.98%
4/26/2023Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$24.00+167.86%
3/7/2023Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$33.00 ➝ $25.00+170.56%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:20 PM ET.












STOK Price Target - Frequently Asked Questions

What is Stoke Therapeutics's consensus rating and price target?

According to the issued ratings of 8 analysts in the last year, the consensus rating for Stoke Therapeutics stock is Moderate Buy based on the current 2 hold ratings and 6 buy ratings for STOK. The average twelve-month price prediction for Stoke Therapeutics is $21.00 with a high price target of $35.00 and a low price target of $12.00. Learn more on STOK's analyst rating history.

Do Wall Street analysts like Stoke Therapeutics more than its competitors?

Analysts like Stoke Therapeutics more than other Medical companies. The consensus rating score for Stoke Therapeutics is 2.75 while the average consensus rating score for medical companies is 2.68. Learn more on how STOK compares to other companies.

Does Stoke Therapeutics's stock price have much upside?

According to analysts, Stoke Therapeutics's stock has a predicted upside of 195.72% based on their 12-month stock forecasts.

What analysts cover Stoke Therapeutics?

Stoke Therapeutics has been rated by Needham & Company LLC in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:STOK) was last updated on 2/29/2024 by MarketBeat.com Staff